Core C: Cell Processing Resource will support each of the four research projects in this grant proposal by providing three specific services. First. Core C will support process development and pre-clinical translation activities, and provide investigators access to the necessary qualified manufacturing facilities, trained staffing, validated equipment and cGMP expertise required for the therapeutic production of the high affinity WT-1 reactive T-cell populations described in Project 3 and the chimeric antigen receptor transduced T-cells detailed in Project 4. This will include evaluating new equipment and technologies, developing novel procedures, and validating any changes to existing processing and quality control assays prior to implementation. Second, the Core will perform flow cytometry staining and analyses for expression of cell surface markers such as HLA-DP in donor peripheral blood in support of Project 1;hematopoietic progenitor cells, B-cells. Monocytes, NK, NKT, and T-cell subsets including helper, suppressor/killer, regulatory, naive and memory fractions to characterize donor PBSC collections and pre/post-treatment patient specimens (Project 2). Such data, when combined with patient outcome results from Core D long-term follow-up, Core B molecular diagnostic, and analyzed by sophisticated statistical methods provided by Core A, will prove to be extremely useful in correlating which cell subsets within the transplant collections are associated with specific clinical outcomes. These results will help to stimulate development of novel graft engineering approaches and techniques that could further improve allogeneic transplantation outcomes. Third, Core C will assist in the procurement of research samples, and will then process, cryopreserve, and distribute those specimens for research studies. These will include donor and patient peripheral blood and/or bone marrow samples, including pre-transplant, post treatment with novel agents (Project 2), and post-relapse (Projects 2, 3, 4). Such research samples have been extensively utilized in the past, and will continue to be useful in defining mechanisms involved in immune reconstitution. relapse, and the development of GvHD that are the main focus areas of this grant application.

Public Health Relevance

Core C is helping to advance cancer therapy by examining associations of specific cell types and the expression of certain surface markers with transplant outcomes, by obtaining and helping to analyze research specimens by molecular and genetic testing to study mechanisms of relapse and development of GvHD, and by supporting the production of novel, more effective, immune cells capable of eradicating residual disease in the patient.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-T)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Humbert, Olivier; Gisch, Don W; Wohlfahrt, Martin E et al. (2016) Development of Third-generation Cocal Envelope Producer Cell Lines for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T-cells. Mol Ther 24:1237-46
Mielcarek, Marco; Furlong, Terry; O'Donnell, Paul V et al. (2016) Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood 127:1502-8
Achille, Nicholas J; Othus, Megan; Phelan, Kathleen et al. (2016) Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leuk Res 42:68-74
Cheng, Guang-Shing; Campbell, Angela P; Xie, Hu et al. (2016) Correlation and Agreement of Handheld Spirometry with Laboratory Spirometry in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 22:925-31
Festuccia, Moreno; Deeg, H Joachim; Gooley, Theodore A et al. (2016) Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. Biol Blood Marrow Transplant 22:1227-33
Green, Margaret L; Leisenring, Wendy; Xie, Hu et al. (2016) Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol 3:e119-27
Sedlak, Ruth Hall; Hill, Joshua A; Nguyen, Thuy et al. (2016) Detection of Human Herpesvirus 6B (HHV-6B) Reactivation in Hematopoietic Cell Transplant Recipients with Inherited Chromosomally Integrated HHV-6A by Droplet Digital PCR. J Clin Microbiol 54:1223-7
Graf, Solomon A; Vaughn, Jennifer E; Chauncey, Thomas R et al. (2016) Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. Biol Blood Marrow Transplant 22:1582-7
Aki, S Z; Inamoto, Y; Carpenter, P A et al. (2016) Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity. Bone Marrow Transplant 51:1350-1353
Gallo, S; Woolfrey, A E; Burroughs, L M et al. (2016) Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD? Bone Marrow Transplant 51:1573-1578

Showing the most recent 10 out of 1809 publications